Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• The relationship between platelet function test results and clinical outcomes in patients with acute coronary syndromes (ACS) managed medically without revascularization remains unclear.
• Understanding these relationships is crucial for optimizing antiplatelet therapy in ACS patients.

Purpose of the Study:

• To compare platelet reactivity between clopidogrel and prasugrel in ACS patients treated medically.
• To evaluate the association between platelet reactivity and clinical outcomes in this patient population.

Main Methods:

• The TRILOGY ACS trial (2008-2011) enrolled patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction.
• A platelet function substudy assessed P2Y12 reaction units (PRUs) at various time points in patients receiving aspirin with either clopidogrel or prasugrel.
• The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction, or stroke through 30 months.

Main Results:

• Prasugrel was associated with significantly lower PRU values compared to clopidogrel across different patient subgroups (age, weight).
• Despite differences in platelet reactivity, no significant difference was found in the primary efficacy endpoint between the prasugrel and clopidogrel groups at 30 months (17.2% vs 18.9%, P = .29).
• No significant relationship was observed between continuous PRU values or high on-treatment platelet reactivity and the occurrence of the primary efficacy endpoint.

Conclusions:

• In medically managed ACS patients, prasugrel consistently reduced platelet reactivity compared to clopidogrel, regardless of patient characteristics or dosage.
• The observed differences in platelet reactivity did not translate into significant differences in major adverse cardiovascular events between the two drugs.
• Platelet reactivity, as measured by PRUs, did not show a significant association with ischemic outcomes in this study population.